FrancophonIA/ELRC3.0 huggingface dataset:
English: Upper gastrointestinal disorders (oesophagitis, oesophageal ulceration, perforation, erosive gastritis, erosive duodenitis; gastro-duodenal ulcer/perforations)*; lower gastrointestinal disorders (small [jejunum and ileum] and large [colon and rectum] intestinal ulcers, colitis and intestinal perforation)*; upper gastro-intestinal symptoms* such as gastralgia (see section 4.4); these ASA-related GI reactions may or may not be associated with haemorrhage, and may occur at any dose of acetylsalicylic acid and in patients with or without warning symptoms or a previous history of serious GI events*.
Estonian: Väga harv, teadmata mulgustumine)*, seedetrakti ülaosa sümptomid* nt gastralgia (vt lõik 4.4); need ASH'st tingitud seedetrakti reaktsioonid võivad olla seotud verejooksuga või mitte ning võivad esineda atsetüülsalitsüülhappe mistahes annusega ja hoiatavate sümptomitega patsientidel või ilma või varasemate seedetrakti tõsiste juhtudega või ilma*; koliit (sh haavandiline või lümfotsütaarne koliit)
English: Depending on your condition, your doctor will determine the length of time for which you need to take Clopidogrel/Acetylsalicylic acid Teva.
Estonian: Sõltuvalt teie seisundist määrab teie arst aja kestuse, mille vältel te peate võtma Clopidogrel/Acetylsalicylic acid Teva't.Kui teil on olnud südameatakk, määratakse ravi vähemalt neljaks nädalaks.
English: a recent surgery (including dental).
Estonian: kui teil on plaanis kirurgiline opreatsioon (sh hambaoperatsioon);
English: No clinical data on exposure to the combination of clopidogrel/acetylsalicylic acid during pregnancy are available.
Estonian: Klopidogreeli/atsetüülsalitsüülhappe kombinatsiooni kasutamise kohta raseduse ajal puuduvad kliinilised andmed.
English: Anaphylactic shock*, serum sickness, anaphylactoid reactions, aggravation of allergic symptoms of food allergy*, cross-reactive drug hypersensitivity
Estonian: Anafülaktiline šokk*, seerumtõbi, anafülaktoidsed reaktsioonid, toiduallergia allergiliste sümptomite süvenemine*, ravimi ristreaktiivne ülitundlikkus tienopüridiinide vahel (nt tiklopidiin, prasugreel) (vt lõik 4.4)*
English: Salicylic acid in the combination of clopidogrel/acetylsalicylic acid has a plasma half-life of approximately 2 hours.
Estonian: Klopidogreeli/atsetüülsalitsüülhappe kombinatsioonis sisalduva salitsüülhappe poolväärtusaeg vereplasmas on ligikaudu 2 tundi.
English: Therefore, the combination of clopidogrel/acetylsalicylic acid should be used with caution in these patients.
Estonian: Seetõttu peab nendel patsientidel kasutama klopidogreeli/atsetüülsalitsüülhappe kombinatsiooni ettevaatlikult.
English: Eye disorders Ear and labyrinth disorders
Estonian: Kõrva ja labürindi kahjustused
English: NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Estonian: MÜÜGILOA HOIDJA NIMI JA AADRESS 12.
English: Film-coated tablet 14 film-coated tablets 28 film-coated tablets 30 film-coated tablets
Estonian: Õhukese polümeerikattega tablett 14 õhukese polümeerikattega tabletti 28 õhukese polümeerikattega tabletti 30 õhukese polümeerikattega tabletti
English: Tablet coating: hypromellose, polydextrose, titanium dioxide (E171), talc, maltodextrin, medium chain triglycerides, iron oxide yellow (E172).
Estonian: Tableti kate: hüpromelloos 15 cP, polüdekstroos, titaandioksiid (E171), talk, maltodekstriin, keskmise ahelaga triglütseriidid, kollane raudoksiid (E172), karmiin (E120), punane raudoksiid (E172).
English: Clopidogrel/Acetylsalicylic acid Teva should be given as a single daily 75 mg/100 mg dose.
Estonian: Clopidogrel/Acetylsalicylic acid Teva't tuleb manustada ühekordse ööpäevase annusena 75 mg/100 mg.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON for bottles
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED KARP pudelitele
English: Patients should be told about the signs and symptoms of GI undesirable effects and what steps to take if they occur (see section 4.8).
Estonian: Patsiente tuleb teavitada seedetrakti kõrvaltoimete ilmingutest ja sümptomitest ning sellest, mida teha, kui need tekivad.
English: GI undesirable effects including stomach pain, heartburn, nausea, vomiting, and GI bleeding may occur.
Estonian: Võivad tekkida seedetrakti kõrvaltoimed, k.a maovalu, kõrvetised, iiveldus, oksendamine ja gastrointestinaalne verejooks.
English: The most common side effect which has been seen with Clopidogrel/Acetylsalicylic acid Teva is bleeding.
Estonian: Clopidogrel/Acetylsalicylic acid Teva kõige sagedamini täheldatud kõrvaltoimeks on veritsus.
English: There is no information concerning overdose with the combination of clopidogrel/acetylsalicylic acid.
Estonian: Klopidogreeli/atsetüülsalitsüülhappe kombinatsiooniga üleannustamise kohta puuduvad andmed.
English: There are no fertility data with the combination of clopidogrel/acetylsalicylic acid.
Estonian: Fertiilsusandmed klopidogreeli/atsetüülsalitsüülhappe kombinatsiooni kohta puuduvad.
English: In addition, due to the presence of ASA, its use is also contraindicated in:
Estonian: ASH sisalduse tõttu on vajalik ettevaatus:
English: Acute liver failure, liver injury, mainly hepatocellular*, hepatitis, elevation of hepatic
Estonian: Äge maksapuudulikkus, maksakahjustus, peamiselt hepatotsellulaarne*, hepatiit, maksaensüümide taseme tõus*, normist erinevad maksafunktsiooni näitajad
English: • ST segment elevation acute myocardial infarction in medically treated patients eligible for
Estonian: perkutaanse koronaarse interventsiooni käigus - ST-segmendi elevatsiooniga ägeda müokardi infarkti korral farmakoteraapiat saavatel patsientidel, kellele on näidustatud trombolüütiline ravi
English: - In patients with non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): The optimal duration of treatment has not been formally established.
Estonian: - ST-segmendi elevatsioonita ägeda koronaarsündroomiga patsientidel (ebastabiilse stenokardia või Q-sakita müokardiinfarkt).
English: What Clopidogrel/Acetylsalicylic acid Teva looks like and contents of the pack Clopidogrel/Acetylsalicylic acid Teva 75 mg/75 mg film-coated tablets are yellow, film-coated capsule shaped tablets.
Estonian: Kuidas Clopidogrel/Acetylsalicylic acid Teva välja näeb ja pakendi sisu Clopidogrel/Acetylsalicylic acid Teva 75 mg/75 mg õhukese polümeerikattega tabletid on kollased, kapslikujulised õhukese polümeerikattega tabletid.
English: What Clopidogrel/Acetylsalicylic acid Teva looks like and contents of the pack Clopidogrel/Acetylsalicylic acid Teva 75 mg/100 mg film-coated tablets are light pink to pink, film-coated capsule shaped tablets.
Estonian: Kuidas Clopidogrel/Acetylsalicylic acid Teva välja näeb ja pakendi sisu Clopidogrel/Acetylsalicylic acid Teva 75 mg/100 mg õhukese polümeerikattega tabletid on heleroosad kuni roosad, kapslikujulised õhukese polümeerikattega tabletid.
English: How to take Clopidogrel/Acetylsalicylic acid Teva
Estonian: Kuidas Clopidogrel/Acetylsalicylic acid Teva't võtta
English: Very rare, not known enzymes*, abnormal liver function test
Estonian: Väga harv, teadmata paresteesia, pearinglus
English: Bleeding time prolonged, neutrophil count decreased, platelet count decreased * Information reported in published information for ASA (frequency “not known”).
Estonian: * Kirjanduses avaldatud teave ASH kohta, esinemissagedus „teadmata“.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen sulphate) and 75 mg of acetylsalicylic acid (ASA).
Estonian: KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Iga tablett sisaldab 75 mg klopidogreeli (vesiniksulfaadina) ja 75 mg atsetüülsalitsüülhapet (ASH).
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen sulphate) and 100 mg of acetylsalicylic acid (ASA).
Estonian: KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Iga tablett sisaldab 75 mg klopidogreeli (vesiniksulfaadina) ja 100 mg atsetüülsalitsüülhapet (ASH).
English: Each tablet contains 75 mg of clopidogrel (as hydrogen sulphate) and 100 mg of acetylsalicylic acid.
Estonian: Iga tablett sisaldab 75 mg klopidogreeli (vesiniksulfaadina) ja 100 mg atsetüülsalitsüülhapet.
English: Each tablet contains 75 mg of clopidogrel (as hydrogen sulphate) and 75 mg of acetylsalicylic acid.
Estonian: Iga tablett sisaldab 75 mg klopidogreeli (vesiniksulfaadina) ja 75 mg atsetüülsalitsüülhapet.
English: Although minor upper GI symptoms, such as dyspepsia, are common and can occur anytime during therapy, physicians should remain alert for signs of ulceration and bleeding, even in the absence of previous GI symptoms.
Estonian: Seedetrakti ülaosa vähene sümptomaatika, nt düspepsia on sage ja võib ilmneda millal iganes ravi ajal.
English: Breast-feeding should be discontinued during treatment with the combination of clopidogrel/acetylsalicylic acid.
Estonian: Ravi ajaks klopidogreeli/atsetüülsalitsüülhappe kombinatsiooniga tuleb imetamine katkestada.
English: How to store Clopidogrel/Acetylsalicylic acid Teva
Estonian: Kuidas Clopidogrel/Acetylsalicylic acid Teva't säilitada
English: Titanium dioxide (E171) Talc
Estonian: Hüpromelloos 15 cP Polüdekstroos Titaandioksiid (E171)
English: While you are taking Clopidogrel/Acetylsalicylic acid Teva:
Estonian: Clopidogrel/Acetylsalicylic acid Teva võtmise ajal:
English: Hepatic impairment
Estonian: - peapööritus.
English: • Hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) and syndrome of asthma, rhinitis, and nasal polyps.
Estonian: ASH sisalduse tõttu on selle kasutamine lisaks vastunäidustatud: - Ülitundlikkuse korral mittesteroidsete põletikuvastaste ainete (MSPVA) vastu ning astmat, riniiti ja ninapolüüpe hõlmava sündroomi korral.
English: Titanium dioxide (E171) Quinoline yellow aluminium lake (E104) Talc
Estonian: Kinoliinkollane alumiiniumlakk (E104)
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen sulphate) and 100 mg of acetylsalicylic acid.
Estonian: TOIMEAINE(TE) SISALDUS Iga tablett sisaldab 75 mg klopidogreeli (vesiniksulfaadina) ja 100 mg atsetüülsalitsüülhapet.
English: Musculoskeletal and connective tissue disorders
Estonian: Lihas-skeleti, sidekoe ja luu kahjustused
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen sulphate) and 75 mg of acetylsalicylic acid.
Estonian: TOIMEAINE(TE) SISALDUS Iga tablett sisaldab 75 mg klopidogreeli (vesiniksulfaadina) ja 75 mg atsetüülsalitsüülhapet.
English: • hearing loss
Estonian: Silma kahjustused
English: Very rare, not known colitis (including ulcerative or lymphocytic colitis), upper gastro-intestinal symptoms* such as gastralgia (see section 4.4), stomatitis.
Estonian: Seedetrakti ja retroperitoneaalne verejooks fataalse lõpuga, pankreatiit, maokaksteistsõrmiku haavand/perforatsioon*, koliit (sh haavandiline või lümfotsütaarne koliit), seedetrakti ülaosa sümptomid* nt gastralgia (vt lõik 4.4), stomatiit.
English: Do not take Clopidogrel/Acetylsalicylic acid Teva
Estonian: Kui te unustate Clopidogrel/Acetylsalicylic acid Teva't võtta
English: • Severe hepatic impairment.
Estonian: - Raske neerukahjustuse korral.
English: Gastrointestinal (GI)
Estonian: Atsetüülsalitsüülhape (ASH):
English: Clopidogrel/Acetylsalicylic acid Teva 75 mg/75 mg film-coated tablets clopidogrel/acetylsalicylic acid
Estonian: Clopidogrel/Acetylsalicylic acid Teva 75 mg/75 mg õhukese polümeerikattega tabletid Klopidogreel/atsetüülsalitsüülhape
English: • jaundice
Estonian: Hematuuria
English: Clopidogrel/Acetylsalicylic acid Teva 75 mg/75 mg
Estonian: Clopidogrel/Acetylsalicylic acid Teva 75 mg/75 mg õhukese polümeerikattega tabletid
English: carmine (E120), iron oxide red (E172).
Estonian: Punane raudoksiid (E172)
English: Clopidogrel/Acetylsalicylic acid Teva 75 mg/100 mg film-coated tablets Clopidogrel/Acetylsalicylic acid
Estonian: Clopidogrel/Acetylsalicylic acid Teva 75 mg/100 mg õhukese polümeerikattega tabletid Klopidogreel/atsetüülsalitsüülhape
English: • indigestion or heartburn.
Estonian: (SSRId) või trombolüütikumidega.
English: NAME OF THE MEDICINAL PRODUCT Clopidogrel/Acetylsalicylic acid Teva 75 mg/100 mg film-coated tablets
Estonian: RAVIMPREPARAADI NIMETUS Clopidogrel/Acetylsalicylic acid Teva 75 mg/100 mg õhukese polümeerikattega tabletid
English: Taste disturbances
Estonian: Seedetrakti häired
English: NAME OF THE MEDICINAL PRODUCT Clopidogrel/Acetylsalicylic acid Teva 75 mg/75 mg film-coated tablets
Estonian: RAVIMPREPARAADI NIMETUS Clopidogrel/Acetylsalicylic acid Teva 75 mg/75 mg õhukese polümeerikattega tabletid
English: Clopidogrel/Acetylsalicylic acid Teva 75 mg/100 mg
Estonian: Clopidogrel/Acetylsalicylic acid Teva 75 mg/100 mg õhukese polümeerikattega tabletid
English: NSAIDs
Estonian: MSPVA-d
English: • Hepatic impairment
Estonian: Omandatud hemofiilia
English: Other concomitant therapy with ASA
Estonian: Muu samaaegne ravi ASH-ga
English: 2 capsules
Estonian: 2 kapslit
English: Sachet (PET/Alu/LLDPE)
Estonian: Kotike (PET/Alu/LLDPE)
English: 1 capsule (125 mg) + 2 capsules (80 mg)
Estonian: 1 kapsel (125 mg) + 2 kapslit (80 mg)
English: Oral use
Estonian: Kõvakapsel
English: 125 mg Powder for oral suspension
Estonian: 125 mg Suukaudse suspensiooni pulber
English: 1 sachet + 2 dispensers + 1 cap + 1 mixing cup
Estonian: 1 kotike + 2 süstalt + 1 kork+ segamistops
English: The marketing authorisation holders should provide convincing and robust data to identify a patient population in which the clinical benefits of ketoconazole-containing products for oral use clearly outweigh the risks.
Estonian: Müügiloa hoidjad peavad esitama veenvad ja üheselt mõistetavad andmed, et määratleda patsiendipopulatsioon, kellele on ketokonasooli sisaldavate suukaudsete ravimite kliiniline kasulikkus selgelt suurem kui kaasnevad riskid.
English: Conditions for lifting the suspension of the Marketing Authorisation(s)
Estonian: Müügiloa (müügilubade) peatamise lõpetamise tingimused
English: Annex III Conditions for lifting the suspension of the Marketing Authorisation(s)
Estonian: III lisa Müügiloa (müügilubade) peatamise lõpetamise tingimused
English: What is Cokiera?
Estonian: Mis on Cokiera?
English: The active substances in Cokiera work in different ways.
Estonian: Cokiera toimeained toimivad erinevalt.
English: The company also provided results of a mathematical (modelling and simulation) exercise to predict the levels of the active substances and the medicine's effectiveness in clearing the virus from the blood in different circumstances.
Estonian: Ettevõte esitas ka (modelleerimise ja simulatsiooni) arvutuslikud tulemused toimeainete eeldatavate sisalduste kohta ja ravimi tõhususe kohta viiruse vereringest eemaldamisel erinevates olukordades.
English: The active substances in Cokiera are effective against hepatitis C virus genotypes 1a and 1b.
Estonian: Cokiera toimeained on tõhusad C-hepatiidi viiruse genotüüpide 1a ja 1b vastu.
English: EMA/541043/2016
Estonian: 16. september 2016 EMA/541043/2016
English: On 3 August 2016, AbbVie Ltd officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Cokiera, for the treatment of chronic hepatitis C.
Estonian: AbbVie Ltd teatas 3. augustil 2016 ametlikult inimravimite komiteele oma soovist võtta tagasi ravimi Cokiera müügiloa taotlus.
English: The CHMP considered that the data provided did not properly show how the size of meals affect absorption of the active substances from Cokiera and therefore how well Cokiera works.
Estonian: Inimravimite komitee oli arvamusel, et esitatud andmed ei näidanud täpselt, kuidas toidukorra suurus mõjutab toimeainete imendumist Cokierast, ning seega ka Cokiera toime tugevust.
English: Cokiera is an antiviral medicine containing the active substances dasabuvir, ombitasvir, paritaprevir and ritonavir.
Estonian: Cokiera on viirusevastane ravim, mis sisaldab toimeaineid dasabuviir, ombitasviir, paritapreviir ja ritonaviir.
English: Because all the active substances in Cokiera were already included in authorised medicines, the company presented the results of studies to see whether the active substances from Cokiera were ‘bioequivalent' to the authorised medicines.
Estonian: Kuna kõiki Cokiera toimeaineid juba turustatakse müügiloaga ravimitena, esitas ettevõte tulemused uuringust, milles uuriti Cokiera toimeainete bioekvivalentsust müügiloaga ravimitega.
English: Therefore, at the time of the withdrawal, the CHMP was of the opinion that the company had not provided enough data to support the application for Cokiera.
Estonian: Seetõttu oli inimravimite komitee müügiloa taotluse tagasivõtmise ajal arvamusel, et ettevõte ei ole esitanud piisavalt andmeid ravimi Cokiera taotluse toetuseks.
English: The company informed the CHMP that there are no ongoing clinical trials or compassionate-use programmes for this specific product.
Estonian: Ettevõte teatas inimravimite komiteele, et antud ravimiga ei viida läbi kliinilisi uuringuid ega eriloaga kasutamise programme.
English: Ritonavir, the fourth active substance, slows down the removal of paritaprevir from the body by blocking an enzyme called CYP3A that breaks down paritaprevir.
Estonian: Neljas toimeaine ritonaviir aeglustab paritapreviiri eemaldamist organismist, blokeerides paritapreviiri lagundavat ensüümi CYP3A.
English: How is Cokiera expected to work?
Estonian: Milline on Cokiera eeldatav toime?
English: In its letter notifying the Agency of the withdrawal of application, the company stated that the withdrawal is based on strategic business reasons for this specific product.
Estonian: Ettevõtte kirjas, milles ta teatab Euroopa Ravimiametile oma taotluse tagasivõtmisest, märgib ettevõte, et võttis taotluse tagasi äristrateegia tõttu.
English: Ritonavir itself does not have an antiviral effect on hepatitis C virus.
Estonian: Ritonaviir ise ei oma C-hepatiidi viiruse vastast toimet.
English: Dasabuvir blocks the action of an enzyme in the hepatitis C virus, called ‘NS5B RNA-dependent polymerase', which the virus needs to multiply.
Estonian: Dasabuviir blokeerib C-hepatiidi viiruse ensüümi nimega NS5B RNA-st sõltuv RNA polümeraas, mida on vaja viiruse paljunemiseks.
English: Based on the review of the data at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Cokiera could not have been approved for the treatment of chronic hepatitis C in adults.
Estonian: Tuginedes esitatud andmete analüüsile, nägi komitee taotluse tagasivõtmise ajal põhjust ettevaatlikkuseks ja oli esialgsel seisukohal, et ravimi Cokiera kasutamist kroonilise C-hepatiidi raviks täiskasvanutel ei ole võimalik heaks kiita.
English: Ombitasvir blocks the action of a protein in the hepatitis C virus called ‘NS5A' and paritaprevir blocks the action of another protein called ‘NS3/4A', both of which the virus needs to multiply.
Estonian: Ombitasviir blokeerib C-hepatiidi viiruse valgu NS5A ja paritapreviir valgu NS3/4A, mida mõlemat vajab viirus paljunemiseks.
English: 16 September 2016 EMA/541043/2016 EMEA/H/C/0004235
Estonian: EMEA/H/C/0004235
English: All four active substances in Cokiera are already available in authorised medicines for treating chronic hepatitis C. It was expected that combining the substances in a single tablet would make it simpler for patients to take their medicine.
Estonian: Eeldati, et toimeainete kombineerimine ühte tabletti muudab ravimi võtmise patsiendile lihtsamaks.
English: What was Cokiera expected to be used for?
Estonian: Milleks kavatseti Cokierat kasutada?
English: Cokiera was expected to be used for treating adults with chronic (long-term) hepatitis C. Hepatitis C is an infection of the liver caused by the hepatitis C virus.
Estonian: Cokierat kavatseti kasutada kroonilise C-hepatiidiga täiskasvanute raviks.
English: Generally, these reactions were mild or moderate.
Estonian: Need reaktsioonid olid üldjuhul kerged või mõõdukad.
English: Cmax was not significantly changed.
Estonian: Cmax oluliselt ei muutunud.
English: Do not give this medicine to children and adolescents under the age of 18 because the potential risks and benefits are not known.
Estonian: Ärge andke seda ravimit alla 18-aastastele lastele ega noorukitele, kuna võimalikud riskid ja kasu ei ole teada.
English: If it is not, do not use the solution.
Estonian: Kui see nii ei ole, ärge lahust kasutage.
English: Hold the syringe in one hand like a pencil.
Estonian: Hoidke süstalt ühes käes nagu pliiatsit.
English: Other medicines and Relistor
Estonian: Muud ravimid ja Relistor
English: Treatment should be initiated as appropriate.
Estonian: Vajaduse korral tuleb alustada ravi.
English: How often this happens is not known from the data that is available.
Estonian: Olemasolevate andmete põhjal ei saa öelda, kui sageli seda juhtub.
English: This section is divided into the following subsections:
Estonian: Käesolev lõik koosneb järgmistest alalõikudest:
English: There is no need to worry about this as it will not affect the accuracy of the dose or pose any risk to your health.
Estonian: Pole tarvis muretseda, sest see ei mõjuta annuse täpsust ega ohusta mingil viisil teie tervist.
English: Always have the outer carton of the medicine with you, even if it is empty.
Estonian: Võtke alati kaasa ravimi välispakend, isegi kui see on tühi.
English: Are you mobile enough to reach the toilet, or do you have a caregiver looking after you who can help?
Estonian: Kas olete tualeti kasutamiseks piisavalt liikuv või teid aitab hooldaja?
English: Wash your hands thoroughly with soap and warm water.
Estonian: Peske käed hoolikalt sooja vee ja seebiga.
English: Avoid repeated injections at the exact same spot previously used.
Estonian: Vältige korduva süsti tegemist täpselt varem kasutatud kohale.
English: This will mean that the safety mechanism has been activated, and the needle will disappear into the syringe.
Estonian: See tähendab, et on aktiveeritud ohutusmehhanism ja nõel kaob süstlasse.
English: The injection volume for these patients should be calculated as follows:
Estonian: Nende patsientide puhul tuleb arvutada süstitav kogus järgmiselt:
English: Your doctor will decide if you can use Relistor if you are pregnant.
Estonian: Teie arst otsustab, kas te võite raseduse ajal Relistori kasutada.
English: The terminal disposition half-life (t1/2) is approximately 8 hours.
Estonian: Lõplik poolväärtusaeg t1/2 on ligikaudu 8 tundi.
English: Has it been 48 hours or longer since your last bowel movement?
Estonian: Kas viimasest sooletühjendusest on möödunud 48 tundi või rohkem?
English: The following side effects are very common and may affect more than 1 in 10 people.
Estonian: Järgnevad kõrvaltoimed on sagedased ja võivad esineda rohkem kui ühel inimesel kümnest.
English: Wincentego Pola 21 58-500 Jelenia Góra, Poland
Estonian: Wincentego Pola 21 58-500 Jelenia Góra, Poola
English: This medicine is for use in adults (aged 18 and over).
Estonian: Käesolev ravim on ette nähtud kasutamiseks täiskasvanutel (alates 18 aasta vanusest).
English: At any time, the patient's assigned dose could be reduced based on tolerability.
Estonian: Patsiendile määratud annust võis igal ajal taluvuse tõttu vähendada.
English: There was no evidence of teratogenicity in rats or rabbits.
Estonian: Teratogeensuse kohta rottidel ja küülikutel tõendid puudusid.
English: When you hear a click sound that means the entire contents were injected.
Estonian: Kui kuulete klõpsu, tähendab see, et kogu sisu on süstitud.
English: • If you are receiving supportive care for your advanced illness, this medicine will only be used for a limited period of time, which will usually be less than 4 months.
Estonian: • Kui te saate oma kaugelearenenud haiguse tõttu toetavat ravi, kasutatakse käesolevat ravimit ainult piiratud aja jooksul, mis on tavaliselt lühem kui 4 kuud.
English: Date of latest renewal: 27 May 2013
Estonian: Müügiloa viimase uuendamise kuupäev: 27. mai 2013
English: Therefore, no dose adjustment is recommended based on age.
Estonian: Seega ei ole vanusest lähtuvalt annuse kohandamine soovitatav.
English: If needed, you may cover the injection site with a plaster.
Estonian: Vajaduse korral võite süstekoha plaastriga katta.